⟵ Back to Search Results

BGB-900-103

Completed

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Beigene Study ID info

BGB-900-103

ClinicalTrials.gov ID info

NCT03666143

China Drug Trials ID info

CTR20181404

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan